China Cancer Drug Misuse In Spotlight After Shocking Whistleblower Tales
Guideline Non-Compliance, Off-Label Use
Using PD-1 immuno-oncology drugs to treat post-surgery gastric cancer and prescribing unapproved targeted therapies for colon cancer are just two examples of the apparently widespread misuse of oncology drugs in China, as alleged by an oncologist at a prestigious Peking university hospital.
You may also be interested in...
A new emergency authorization marks China’s fourth approval for inactivated COVID-19 vaccines, despite lingering doubts over the protection offered by the technology and surging cases in one of the most vaccinated countries where Sinopharm’s inactivated vaccines are widely used.
China's latest national census data paint a mixed picture for the provision of health in the world’s most populous nation, with multiple major trends potentially impacting areas of opportunity.
Originated by a Suzhou-based biotech founded two years ago and now being jointly developed with WalVax, China’s first homegrown mRNA COVID-19 vaccine is now entering the final stages of development.